Mayo Clinic Cancer Center — Research

Below are current clinical trials.

2051 studies in Mayo Clinic Cancer Center — Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. Combination Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Young Patients with Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

   Rochester, Minn.

   This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work when given before a peripheral stem cell transplant in treating young patients with newly diagnosed supratentorial primitive neuroectodermal tumors or high-risk medulloblastoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with a peripheral stem cell transplant may allow more chemotherapy to be given so that more tumor cells are killed. It is not yet known which combination chemotherapy regimen is more effective when given before a peripheral stem cell transplant in treating supratentorial primitive neuroectodermal tumors or medulloblastoma.

2. Low-Dose or High-Dose Lenalidomide in Treating Children with Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

   Rochester, Minn.

   This randomized phase II trial studies how well low-dose lenalidomide works compared with high-dose lenalidomide in treating children with juvenile pilocytic astrocytomas or optic nerve pathway gliomas that have come back (recurrent), have not responded to treatment (refractory), or are growing, spreading, or getting worse (progressive). Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether low-dose lenalidomide is more or less effective than high-dose lenalidomide in treating patients with juvenile pilocytic astrocytomas or optic nerve pathway gliomas.

3. Combination Vaccine Immunotherapy (DRibbles) for Patients with Definitively-treated Stage III Non-small Cell Lung Cancer

   Scottsdale/Phoenix, Ariz.

   This study will test an investigational vaccine, called DRibbles, for the treatment of non-small cell lung cancer (NSCLC). We hypothesize that vaccination with the DRibble vaccine will cause an immune response against proteins contained in the DRibble vaccine and the protein antigens targeted by this strong immune response will include common antigens shared by both the vaccine and the patient's tumor.

4. Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer

   Mankato, Minn.

   RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Chemoradiotherapy (combining chemotherapy with radiation therapy) before surgery may shrink the tumor so that it can be removed. Giving chemotherapy after surgery may kill any remaining tumor cells.

   PURPOSE: This randomized phase II trial is studying two different regimens of neoadjuvant chemoradiotherapy and adjuvant chemotherapy and comparing how well they work in treating patients who are undergoing surgical resection for locally advanced rectal cancer.

5. A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

   Rochester, Minn.

   The purpose of this study is to determine whether oral rucaparib is effective in the treatment of patients with locally advanced or metastatic pancreatic cancer and a known deleterious BRCA mutation.

6. Study of Blood Samples From Newborns with Down Syndrome

   Rochester, Minn.

   RATIONALE: Studying the genes expressed in samples of blood from patients with Down syndrome may help doctors identify biomarkers related to cancer.

   PURPOSE: This research study is looking at blood samples from newborns with Down syndrome.

7. A Study to Evaluate Exemestane in Post-Menopausal Women with Non-Small Cell Lung Cancer (NSCLC)

   Albert Lea, Minn., Mankato, Minn.

   This study is being conducted to see if adding Exemestane to the immune checkpoint blockade can slow disease progression in post-menopausal women with non-small cell lung cancer.

8. A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

   Rochester, Minn.

   This research study is studying Daratumumab as a possible treatment for Waldenström Macroglobulinemia.

9. Spatial and Molecular Architecture of Tumor Environments Responsive to IO (immuno-oncology) Therapy

   Rochester, Minn.

   The purpose of this study is to gain stepwise understanding of the fundamental biology governing human antitumor immunity, by systematic study of the tumor-immune interface at the level of the TME, taking advantage of the heterogeneity of different interacting tumor and immune cell subsets.

10. Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

    Rochester, Minn.

    Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma